Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass.
To evaluate the possible protective effects of fenoldopam on renal function in patients undergoing cardiopulmonary bypass. Prospective, randomized trial. University teaching hospital. One hundred sixty consecutive patients with serum creatinine >1.5 mg/dL who underwent uncomplicated moderate hypothermic cardiopulmonary bypass for cardiac surgery. A random group of 80 patients was managed conventionally (group A), whereas another random group of 80 patients received continuous intravenous administration of low-dose fenoldopam (0.1-0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B). An improvement of postoperative renal parameters were observed only in group B: preoperative serum creatinine 1.82 +/- 0.2 versus 1.43 +/- 0.73 postoperatively (p < 0.001), preoperative creatinine clearance 51.34 +/- 22.26 versus 67.14 +/- 18.55 postoperatively (p < 0.001). In this study, fenoldopam was an effective agent in the prevention of renal dysfunction after cardiopulmonary bypass.